Literature DB >> 21994900

Prevalence and spectrum of microsatellite alterations in nonmuscle invasive bladder cancers.

Guillaume Legrand1, Hany Soliman, Francis Dubosq, Jérôme Vérine, François Desgrandchamps, Hugues de Thé, Pierre Mongiat-Artus, Guillaume Ploussard.   

Abstract

We aimed to identify interesting deleted chromosomal regions for bladder cancer diagnosis and carcinogenesis, and to evaluate the association between loss of heterozygosity (LOH) and clinico-pathological parameters. Microsatellite analysis was performed on urine sediment and tumor tissue from 43 consecutive patients with superficial transitional cell carcinoma (TCC) and from 42 consecutive controls. Informative cases were scored as LOH or allelic loss (AL) according to the decrease of the allelic-imbalance ratio. The prevalence of LOH and AL was 39.5% and 86%, respectively. Chromosome 9 was the most frequently altered, especially at 9p (35%). The total number of microsatellite alterations per analysis was correlated with age, grade, stade and EAU classification. The locus 17p13.1 was strongly associated with high-stage (p=0.01) and high-grade tumors (p=0.02). Specificity and sensitivity of LOH was 100% and 39.3% for diagnosis of malignant urinary disease. Specificity and sensitivity of AL was 73.8% and 88%, respectively. Allelic losses are a frequent and early event in bladder cancer, especially at 9p. Thanks to its high specificity, LOH may serve as a complementary tool for non invasive diagnosis of bladder cancer. Further study is warranted to evaluate the prognostic value of LOH on recurrence, progression and muscle invasion.

Entities:  

Keywords:  Bladder cancer; allelic loss; loss of heterozygosity; microsatellite

Year:  2011        PMID: 21994900      PMCID: PMC3189821     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  33 in total

1.  Microsatellite analysis of free tumor DNA in urine, serum, and plasma of patients: a minimally invasive method for the detection of bladder cancer.

Authors:  Michael Utting; Wolfram Werner; Regine Dahse; Jörg Schubert; Kerstin Junker
Journal:  Clin Cancer Res       Date:  2002-01       Impact factor: 12.531

2.  Microsatellite analysis--DNA test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma: a phase II trial.

Authors:  B W van Rhijn; I Lurkin; W J Kirkels; T H van der Kwast; E C Zwarthoff
Journal:  Cancer       Date:  2001-08-15       Impact factor: 6.860

3.  Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations.

Authors:  A R Simoneau; C H Spruck; M Gonzalez-Zulueta; M L Gonzalgo; M F Chan; Y C Tsai; M Dean; K Steven; T Horn; P A Jones
Journal:  Cancer Res       Date:  1996-11-01       Impact factor: 12.701

4.  Use of polymerase chain reaction analysis of urinary DNA to detect bladder carcinoma.

Authors:  Brian Little; Anne Hughes; Michael R A Young; Aiden O'Brien
Journal:  Urol Oncol       Date:  2005 Mar-Apr       Impact factor: 3.498

5.  Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder.

Authors:  Johanna M M van Oers; Christoph Adam; Stefan Denzinger; Robert Stoehr; Simone Bertz; Dirk Zaak; Christian Stief; Ferdinand Hofstaedter; Ellen C Zwarthoff; Theodorus H van der Kwast; Ruth Knuechel; Arndt Hartmann
Journal:  Int J Cancer       Date:  2006-09-01       Impact factor: 7.396

6.  Evaluation of microsatellite analysis in urine sediment for diagnosis of bladder cancer.

Authors:  A Schneider; S Borgnat; H Lang; O Régine; V Lindner; M Kassem; C Saussine; P Oudet; D Jacqmin; M P Gaub
Journal:  Cancer Res       Date:  2000-08-15       Impact factor: 12.701

7.  Non-invasive molecular detection of bladder cancer recurrence.

Authors:  Najla Amira; Samia Mourah; François Rozet; Pierre Teillac; Jean Fiet; Philippe Aubin; Ariane Cortesse; François Desgrandchamps; Alain Le Duc; Olivier Cussenot; Hany Soliman
Journal:  Int J Cancer       Date:  2002-09-20       Impact factor: 7.396

8.  Role of chromosome 9 in human bladder cancer.

Authors:  N Miyao; Y C Tsai; S P Lerner; A F Olumi; C H Spruck; M Gonzalez-Zulueta; P W Nichols; D G Skinner; P A Jones
Journal:  Cancer Res       Date:  1993-09-01       Impact factor: 12.701

9.  Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]).

Authors:  Madelon N M van der Aa; Ellen C Zwarthoff; Ewout W Steyerberg; Merel W Boogaard; Yvette Nijsen; Kirstin A van der Keur; Antonius J A van Exsel; Wim J Kirkels; Chris Bangma; Theo H van der Kwast
Journal:  Eur Urol       Date:  2008-05-15       Impact factor: 20.096

10.  Destabilization of chromosome 9 in transitional cell carcinoma of the urinary bladder.

Authors:  F Kimura; A R Florl; H H Seifert; J Louhelainen; S Maas; M A Knowles; W A Schulz
Journal:  Br J Cancer       Date:  2001-12-14       Impact factor: 7.640

View more
  2 in total

1.  Multivariate analysis of the prognostic significance of resection weight after transurethral resection of bladder tumor for non-muscle-invasive bladder cancer.

Authors:  Dae Hyeon Kwon; Phil Hyun Song; Hyun Tae Kim
Journal:  Korean J Urol       Date:  2012-07-19

2.  A novel transurethral resection technique for superficial flat bladder tumor: grasp and bite technique.

Authors:  Kyung Jin Oh; Yoo-Duk Choi; Ho Suck Chung; Eu Chang Hwang; Seung Il Jung; Dong Deuk Kwon; Kwangsung Park; Taek Won Kang
Journal:  Korean J Urol       Date:  2015-02-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.